Satori gains $22M to push Alzheimer's work

Satori Pharmaceuticals has raised $22 million to advance new drugs designed to stop Alzheimer's at an early stage. InterWest Partners, Prospect Venture Partners, New Enterprise Associates, PureTech Ventures joined existing investors in the venture round, according to a report in Xconomy.

Satori has been working to advance new therapies that block the development of toxic proteins. And it's been working with researchers in academia to find biomarkers that can send an early warning about the onset of Alzheimer's so people can be treated early enough to prevent or delay the disease.

"This would be something where you come in to the doctor with some memory loss that's more than just about how you forgot where you put the car keys, but you haven't yet gotten to the point where you can't remember your daughter's name," Satori CEO Jeff Ives tells Xconomy.

There's no set timeline in place, but Ives hopes to get into the clinic in 2010, seeking data on a new therapy that could be taken regularly for years without triggering an adverse reaction in an aging population that will be taking multiple meds.

- here's Satori's release
- read the report from Xconomy

Related Articles:
Researchers herald breakthrough data on Alzheimer's
New direction for Alzheimer's research?

ALSO: Vivaldi Biosciences has raised $23 million in a Series A Convertible Preferred Stock financing, of which $18,850,000 has been funded. Release